AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations
阿斯利康的日本阿科拉米德治疗转甲状腺素介导淀粉样心肌病（ATTR-CM）的3期试验结果与BridgeBio Pharma的Atribute-CM 3期试验一致，包括存活率、心脏相关住院治疗
